COMPASS Pathways plc (CMPS) Stock Analysis & Investment Frameworks
COMPASS Pathways plc (CMPS) stock analysis on Invetso. Review COMPASS Pathways plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
COMPASS Pathways plc Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
COMPASS Pathways plc Key Financial Metrics
- Market Cap: $1.18B
- Revenue: $N/A
- ROE: -212.85%
- ROIC: -99.30%
- Dividend Yield: N/A
About COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.